Stock market today: S&P 500 closes at fresh record ahead of Nvidia earnings
Investing.com - BofA Securities initiated coverage on Ambiq Micro Inc (NYSE:AMBQ) with a Neutral rating and a $42.00 price target on Monday, representing about 9% upside from the current price of $38.47. According to InvestingPro data, the stock has shown high price volatility, trading between $32.89 and $51.76 over the past 52 weeks.
The firm cited Ambiq’s position as a manufacturer of ultra-low-power processors for data and AI processing in smartwatches and health-related wearables, with the company’s Apollo-branded chips having shipped in more than 270 million devices to date. The company, currently valued at $670 million, maintains strong financial health with a current ratio of 5.61 and more cash than debt on its balance sheet.
BofA highlighted Ambiq’s superior power efficiency for extended battery life and edge AI capabilities for on-device inferencing as key strengths, while noting the company remains at least three years away from profitability with significant operating and capital expenditures required for future growth.
The research firm also expressed concern about Ambiq’s dependence on two to three customers whose products are cyclical and competitive by nature, factors that contributed to the Neutral stance despite projections of 27% sales CAGR from 2025-2027.
Ambiq Micro is scheduled to report its second-quarter 2025 earnings on September 4th after market close.
In other recent news, Ambiq Micro completed its initial public offering, raising $110.4 million by selling 4.6 million shares at $24 each. The offering included the full exercise of underwriters’ option to purchase an additional 600,000 shares. Ambiq’s shares began trading on the New York Stock Exchange under the symbol "AMBQ." The company has attracted attention from several analyst firms, with Needham initiating coverage with a Buy rating and a $48.00 price target, citing Ambiq’s differentiated technology for AI applications. Stifel also started coverage with a Buy rating and a $45.00 price target, highlighting the company’s proprietary SPOT platform as a competitive advantage. Meanwhile, UBS initiated coverage with a Neutral rating and a $40.00 price target, pointing to valuation concerns despite recognizing Ambiq’s valuable intellectual property. These developments reflect growing interest in Ambiq’s potential in the AI and semiconductor markets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.